GlassScriptPhysician profile
Taylor Wilson
NPI 1710573134
$2,304.83
in general payments reported to CMS, 2019-2025
16 companies · $1,482 in 2025
The $1,482 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $116 · 2024: $707 · 2025: $1,482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,188.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $416.46 | 2024-2025 | |
| Novo Nordisk INC | $413.87 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Antares Pharma, INC. | $284.54 | 2024-2025 | Xyosted |
| Glaxosmithkline, LLC. | $217.29 | 2022-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $211.67 | 2025 | Airsupra |
| Kowa Pharmaceuticals America, INC. | $166.79 | 2024-2025 | Zoryve |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $160.32 | 2025 | Xifaxan |
| Lilly USA, LLC | $129.69 | 2025 | Mounjaro, Zepbound |
| Amgen INC. | $64.50 | 2024 | Repatha, Otezla |
| Acella Pharmaceuticals, LLC | $60.59 | 2024-2025 | NP Thyroid 60 |
| Gilead Sciences, INC. | $35.29 | 2025 | |
| Astellas Pharma US INC | $34.41 | 2025 | Veozah |
| Exact Sciences Corporation | $32.08 | 2025 | The Cologuard Plus Collection Kit |
| Almatica Pharma LLC | $29.37 | 2025 | Loreev Xr |
| Otsuka America Pharmaceutical, INC. | $27.00 | 2025 | Rexulti |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lucid Diagnostics INC. | $20.96 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.